Dileep Kumar Murala
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dileep Kumar Murala has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Sandeep Kumar Panda
ICFAI Foundation for Higher Education
5 shared publications - K. Varaprasada Rao
ICFAI Foundation for Higher Education
3 shared publications - Eric Hitimana
Department of Computer and Software Engineering, University of Rwanda – College of Science and Technology Official Institutional, Kigali, Rwanda
2 shared publications - Madhura Kasaragod
Manipal Institute of Technology Bengaluru, Manipal Academy of Education, Manipal, India
2 shared publications - Abdirahman Khalif Mohamud
Africa Center for Disease Control and Prevention (Africa CDC), Addis Ababa, Ethiopia
1 shared publication - Adapa Gopi
Department of Computer Science and Engineering, Koneru Lakshmaiah Education Foundation, Guntur, India
1 shared publication
Latest Publications
- Open Access
- 27 October 2026
- Published by Springer Nature in Discover Computing
- Vol. 29 (1) , 810
AI-Driven multimodal sensing and secure data frameworks for next-generation biomedical wearable health monitoring systems
- 27 October 2026
- Published by Springer Nature in Discover Computing
- Vol. 29 (1) , 810
Open AccessAI-Driven multimodal sensing and secure data frameworks for next-generation biomedical wearable health monitoring systems
- 1 September 2026
- Published by Taylor & Francis
- p. 281-296
Blockchain-Based Intelligent Transportation Management System
Rapid urbanisation and rising vehicular traffic require effective and intelligent transportation management systems. This chapter proposes using blockchain technology to improve intelligent transportation systems (ITS) efficiency, transparency, and security. Blockchain, advanced data analytics, and machine learning algorithms are used to optimise traffic flow, reduce congestion, and increase transportation safety. Blockchain's decentralised and immutable ledger ensures reliable data exchange among various stakeholders, including vehicles, traffic management authorities, and infrastructure providers. The system employs smart contracts to automate processes such as toll collection, parking management, and vehicular communication, thereby reducing human intervention and the potential for errors. Additionally, real-time data processing and predictive analytics enable dynamic traffic management and incident response. The proposed blockchain-based intelligent transportation management system (BBBITMS) promises to revolutionise urban mobility by providing a scalable, secure, and intelligent framework for future transportation networks. Preliminary simulations and case studies demonstrate the feasibility and effectiveness of the BBBITMS in various urban scenarios.
- 1 September 2026
- Published by Taylor & Francis
- p. 281-296
Blockchain-Based Intelligent Transportation Management System
Rapid urbanisation and rising vehicular traffic require effective and intelligent transportation management systems. This chapter proposes using blockchain technology to improve intelligent transportation systems (ITS) efficiency, transparency, and security. Blockchain, advanced data analytics, and machine learning algorithms are used to optimise traffic flow, reduce congestion, and increase transportation safety. Blockchain's decentralised and immutable ledger ensures reliable data exchange among various stakeholders, including vehicles, traffic management authorities, and infrastructure providers. The system employs smart contracts to automate processes such as toll collection, parking management, and vehicular communication, thereby reducing human intervention and the potential for errors. Additionally, real-time data processing and predictive analytics enable dynamic traffic management and incident response. The proposed blockchain-based intelligent transportation management system (BBBITMS) promises to revolutionise urban mobility by providing a scalable, secure, and intelligent framework for future transportation networks. Preliminary simulations and case studies demonstrate the feasibility and effectiveness of the BBBITMS in various urban scenarios.
- Open Access
- 11 August 2026
- Published by Springer Nature in Discover Applied Sciences
- Vol. 8 (11)
A adaptive SLA-based resource management framework for optimizing performance frontiers in blockchain-as-a-service
- 11 August 2026
- Published by Springer Nature in Discover Applied Sciences
- Vol. 8 (11)
Open AccessA adaptive SLA-based resource management framework for optimizing performance frontiers in blockchain-as-a-service
- Open Access
- 27 July 2026
- Published by Springer Nature in Discover Internet of Things
- Vol. 6 (1)
Medshield a privacy enhanced threat detection framework for secure industrial IoT healthcare
- 27 July 2026
- Published by Springer Nature in Discover Internet of Things
- Vol. 6 (1)
Open AccessMedshield a privacy enhanced threat detection framework for secure industrial IoT healthcare
- 23 June 2026
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 40 (1)
Multimodal machine learning and deep graph neural networks for the prediction of molecular inhibitory activity and disease associations
Effectively integrating a variety of biological and chemical data sources is essential for the acceleration of drug discovery and precision diagnostics. Nevertheless, conventional computational methods frequently experience modality isolation, which results in their inability to simultaneously capture the intricate multi-omics regulatory landscape of diseases and the detailed electronic properties of potential drug molecules.. State-of-the-art models typically depend on one-dimensional SMILES representations or two-dimensional molecular signatures (e.g., ECFP4). Although these representations are computationally efficient, they substantially compress or disregard critical three-dimensional spatial arrangements and electronic characteristics that are essential for precise molecular interaction analysis. In addition, numerous existing drug-disease association models fail to account for the multi-scale topological regulatory signals that are present in heterogeneous biological networks. In complex maladies, such as calcific aortic valve disease (CAVD) and multidrug-resistant infections, this limitation results in diminished predictive performance. This study suggests a unified multimodal deep learning framework that incorporates molecular property prediction with genomic target identification to overcome these challenges. To be more precise, we present an Improved Convolutional Neural Network (ICNN) that has been optimised for omics-based target detection using Honey Bee Mating Optimisation (HBMO). Additionally, a Multi-scale Diffusion Graph Convolutional Network (MsDGCN) is implemented to significantly enhance the modelling of drug-disease relationships. Quantum-calculated three-dimensional electron density grids, which incorporate approximately 125 million data points, are a significant innovation of this work. By converting these grids into structured point cloud representations, it is possible to accurately characterise non-covalent interaction (NCI) regions with high resolution. Kernel Principal Component Analysis (KPCA) is executed to reduce the dimensionality of multimodal data. In addition, an attention-based fusion layer is intended to dynamically prioritise contributions from electronic, sequential, and structural data modalities.In an effort to enhance the robustness of the model, a hard negative mining strategy is implemented to more effectively differentiate between physiologically realistic confounding samples, thereby resolving class imbalance concerns. The proposed framework's successful scalability and robustness across numerous benchmark datasets are illustrated by experimental evaluations. Compared to conventional ECFP4-based models, the incorporation of three-dimensional electronic descriptors leads to a 9.1% increase in Area Under the Curve (AUC). Peak AUC of 0.98 is achieved by the fully fused framework. In addition, the biological relevance of the predictions is confirmed by molecular dynamics simulations that were conducted over a period of 50 ns. HLA-DRA is identified as a novel therapeutic target in CAVD by the framework, and stable natural product inhibitors, such as Chrysin, are predicted. Overall, the proposed system offers a scalable and high-precision platform for the real-world virtual drug screening and clinical biomarker discovery.
- 23 June 2026
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 40 (1)
Multimodal machine learning and deep graph neural networks for the prediction of molecular inhibitory activity and disease associations
Effectively integrating a variety of biological and chemical data sources is essential for the acceleration of drug discovery and precision diagnostics. Nevertheless, conventional computational methods frequently experience modality isolation, which results in their inability to simultaneously capture the intricate multi-omics regulatory landscape of diseases and the detailed electronic properties of potential drug molecules.. State-of-the-art models typically depend on one-dimensional SMILES representations or two-dimensional molecular signatures (e.g., ECFP4). Although these representations are computationally efficient, they substantially compress or disregard critical three-dimensional spatial arrangements and electronic characteristics that are essential for precise molecular interaction analysis. In addition, numerous existing drug-disease association models fail to account for the multi-scale topological regulatory signals that are present in heterogeneous biological networks. In complex maladies, such as calcific aortic valve disease (CAVD) and multidrug-resistant infections, this limitation results in diminished predictive performance. This study suggests a unified multimodal deep learning framework that incorporates molecular property prediction with genomic target identification to overcome these challenges. To be more precise, we present an Improved Convolutional Neural Network (ICNN) that has been optimised for omics-based target detection using Honey Bee Mating Optimisation (HBMO). Additionally, a Multi-scale Diffusion Graph Convolutional Network (MsDGCN) is implemented to significantly enhance the modelling of drug-disease relationships. Quantum-calculated three-dimensional electron density grids, which incorporate approximately 125 million data points, are a significant innovation of this work. By converting these grids into structured point cloud representations, it is possible to accurately characterise non-covalent interaction (NCI) regions with high resolution. Kernel Principal Component Analysis (KPCA) is executed to reduce the dimensionality of multimodal data. In addition, an attention-based fusion layer is intended to dynamically prioritise contributions from electronic, sequential, and structural data modalities.In an effort to enhance the robustness of the model, a hard negative mining strategy is implemented to more effectively differentiate between physiologically realistic confounding samples, thereby resolving class imbalance concerns. The proposed framework's successful scalability and robustness across numerous benchmark datasets are illustrated by experimental evaluations. Compared to conventional ECFP4-based models, the incorporation of three-dimensional electronic descriptors leads to a 9.1% increase in Area Under the Curve (AUC). Peak AUC of 0.98 is achieved by the fully fused framework. In addition, the biological relevance of the predictions is confirmed by molecular dynamics simulations that were conducted over a period of 50 ns. HLA-DRA is identified as a novel therapeutic target in CAVD by the framework, and stable natural product inhibitors, such as Chrysin, are predicted. Overall, the proposed system offers a scalable and high-precision platform for the real-world virtual drug screening and clinical biomarker discovery.
- 4 May 2026
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 40 (1)
Geometric deep reinforcement learning with hierarchical variational autoencoders for de novo drug design and activity optimization
Traditional drug discovery is a resource-intensive process with high attrition rates and the huge difficulty of working with a chemical space that is thought to include [Formula: see text] molecules. Even though computational chemistry has come a long way, traditional generative models still use string-based representations like SMILES, which have trouble capturing intricate three-dimensional spatial interactions and often make structures that aren't real. Moreover, current reinforcement learning methodologies frequently do not achieve an equilibrium between molecular diversity and high-affinity biological activity. To overcome these constraints, this research introduces an innovative integrated framework that merges Geometric Multi-Discrete Soft Actor-Critic (Geom-SAC) and Multi-stage Variational Autoencoders (MS-VAE) to improve de novo molecular creation and activity optimisation. The main new idea is the combination of geometric deep learning, which enforces physical atomic restrictions, and a hierarchical VAE architecture, which organises the latent space into manageable structural steps from scaffold formation to functional group optimisation. We also use a Non-Covalent Interaction-Aware (NCIA) graph neural network in our method to improve protein-ligand affinity predictions by simulating complex intermolecular forces. Experimental results on benchmark datasets, such as ZINC250k and PDBbind, show that the proposed framework improves binding affinity scores by 15% and the Valid-Unique-Novel (VUN) molecule ratio by 20% compared to the best existing methods. Also, adding a security layer based on blockchain technology makes sure that data is secure and can be tracked. This all-encompassing method provides a strong, highly accurate answer for next-generation AI-driven pharmacology. It greatly narrows the gap between computational design and experimental validation.
- 4 May 2026
- Published by Springer Nature in Journal of Computer-Aided Molecular Design
- Vol. 40 (1)
Geometric deep reinforcement learning with hierarchical variational autoencoders for de novo drug design and activity optimization
Traditional drug discovery is a resource-intensive process with high attrition rates and the huge difficulty of working with a chemical space that is thought to include [Formula: see text] molecules. Even though computational chemistry has come a long way, traditional generative models still use string-based representations like SMILES, which have trouble capturing intricate three-dimensional spatial interactions and often make structures that aren't real. Moreover, current reinforcement learning methodologies frequently do not achieve an equilibrium between molecular diversity and high-affinity biological activity. To overcome these constraints, this research introduces an innovative integrated framework that merges Geometric Multi-Discrete Soft Actor-Critic (Geom-SAC) and Multi-stage Variational Autoencoders (MS-VAE) to improve de novo molecular creation and activity optimisation. The main new idea is the combination of geometric deep learning, which enforces physical atomic restrictions, and a hierarchical VAE architecture, which organises the latent space into manageable structural steps from scaffold formation to functional group optimisation. We also use a Non-Covalent Interaction-Aware (NCIA) graph neural network in our method to improve protein-ligand affinity predictions by simulating complex intermolecular forces. Experimental results on benchmark datasets, such as ZINC250k and PDBbind, show that the proposed framework improves binding affinity scores by 15% and the Valid-Unique-Novel (VUN) molecule ratio by 20% compared to the best existing methods. Also, adding a security layer based on blockchain technology makes sure that data is secure and can be tracked. This all-encompassing method provides a strong, highly accurate answer for next-generation AI-driven pharmacology. It greatly narrows the gap between computational design and experimental validation.
- 27 March 2026
- Published by Springer Nature
- p. 237-249
SSI-Trust: A Blockchain-Based Framework for Trusted Issuer Management in Self-Sovereign Identity
- 27 March 2026
- Published by Springer Nature
- p. 237-249
SSI-Trust: A Blockchain-Based Framework for Trusted Issuer Management in Self-Sovereign Identity
- Open Access
- 5 March 2026
- Published by Springer Nature in Discover Applied Sciences
- Vol. 8 (4)
Machine learning-driven advancements in next-generation cognitive radar systems
- 5 March 2026
- Published by Springer Nature in Discover Applied Sciences
- Vol. 8 (4)
Open AccessMachine learning-driven advancements in next-generation cognitive radar systems
- Top Cited PapersOpen Access
- 14 January 2026
- Published by Springer Nature in Discover Internet of Things
- Vol. 6 (1)
Trustfed a scalable privacy preserving federated AI framework for industrial IoT healthcare and finance
- 14 January 2026
- Published by Springer Nature in Discover Internet of Things
- Vol. 6 (1)
Top Cited PapersOpen AccessTrustfed a scalable privacy preserving federated AI framework for industrial IoT healthcare and finance
- Open Access
- 20 November 2025
- Published by Elsevier in Franklin Open
- Vol. 13
BlockDrugChain: A blockchain and ML-driven framework for scalable drug discovery management
- 20 November 2025
- Published by Elsevier in Franklin Open
- Vol. 13
Open AccessBlockDrugChain: A blockchain and ML-driven framework for scalable drug discovery management